Immunosuppression-related hepatitis B virus (HBV) reactivation has received increasing clinical attention because of the widespread use of potent immunosuppressive agents, including chemotherapeutic drugs, molecularly targeted therapies, and immune checkpoint inhibitors. HBV reactivation occurs in 20%–70% of patients with non-Hodgkin lymphoma and can lead to severe hepatitis, liver failure, and death.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Haiyan
Contact Haiyan, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack